Advanced search
Publication Cover
Leukemia & Lymphoma Volume 53, 2012 - Issue 3
Submit an article Journal homepage
943
Views
49
CrossRef citations to date
0
Altmetric
Research Article

Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia

Clemens-Martin WendtnerDepartment I of Internal Medicine, Center of Integrated Oncology (CIO), CECAD, University of Cologne, Cologne, GermanyCorrespondence[email protected]
,
Peter HillmenDepartment of Haematology, St. James's University Hospital, Leeds, UK
,
Daruka MahadevanArizona Cancer Center, Tucson, AZ, USA
,
Andreas BühlerInternal Medicine III, University of Ulm, Ulm, Germany
,
Lutz UharekHematology and Oncology, Charité University Medicine Berlin, Medical Clinic III, Berlin, Germany
,
Steven CoutréStanford University School of Medicine, Stanford, CA, USA
,
Olga FrankfurtRobert H. Lurie CCC, Northwestern University, Chicago, IL, USA
,
Adrian BloorChristie NHS Foundation Trust, Manchester, UK
,
Francesc BoschDepartment of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain
,
Richard R. FurmanWeill Medical College of Cornell University, New York, NY, USA
,
Eva KimbyKarolinska University Hospital, Stockholm, Sweden
,
John G. GribbenCentre for Haemato-Oncology, Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
,
Marco GobbiChair of Hematology, University of Genoa, Genoa, Italy
,
Luke DreisbachDesert Hematology Oncology Medical Group, Inc., Banning, CA, USA
,
David D. HurdWake Forest University, Winston-Salem, NC, USA
,
Mikkael A. SekeresCleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
,
Alessandra FerrajoliDepartment of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Sheetal ShahCelgene Corporation, Summit, NJ, USA
,
Jennie ZhangCelgene Corporation, Summit, NJ, USA
,
Laure Moutouh-de ParsevalCelgene Corporation, Summit, NJ, USA
,
Michael HallekDepartment I of Internal Medicine, Center of Integrated Oncology (CIO), CECAD, University of Cologne, Cologne, Germany
,
Nyla A. HeeremaDepartment of Pathology, The Ohio State University, Columbus, OH, USA
,
Stephan StilgenbauerInternal Medicine III, University of Ulm, Ulm, Germany
&
Asher A. Chanan-KhanRoswell Park Cancer Institute, Buffalo, NY, USACorrespondence[email protected]
[email protected]
 show all
Pages 417-423 | Received 29 Mar 2011, Accepted 20 Aug 2011, Published online: 15 Nov 2011

Citations (49)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (9)

Shimrit Ringelstein-Harlev. (2020) Immune dysfunction complexity in chronic lymphocytic leukemia ‒ an issue to consider when designing novel therapeutic strategies. Leukemia & Lymphoma 61:9, pages 2050-2058.
Read now
Marc Sorigue, Elisa Orna & Juan-Manuel Sancho. (2018) Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review. Leukemia & Lymphoma 59:11, pages 2602-2611.
Read now
Satyen Harish Gohil, Nicola Maciocia, Pip Patrick, Thomas Roberts, Nicholas Counsell, Paul Smith, Laura Clifton-Hadley, Kate Cwynarski, Andrew Pettitt & Amit Chunilal Nathwani. (2018) LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia & Lymphoma 59:7, pages 1730-1733.
Read now
Gilad Itchaki & Jennifer R. Brown. (2017) Lenalidomide in the treatment of chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs 26:5, pages 633-650.
Read now
Punit L. Jain, Carrie Anne Orlikowski & Alessandra Ferrajoli. (2016) Lenalidomide in chronic lymphocytic leukemia. Expert Opinion on Orphan Drugs 4:9, pages 971-980.
Read now
Clemens M. Wendtner, Michael Hallek, Graeme A. M. Fraser, Anne-Sophie Michallet, Peter Hillmen, Jan Dürig, Matt Kalaycio, John G. Gribben, Stephan Stilgenbauer, Andreas Buhler, Thomas J. Kipps, Brendan Purse, Jennie Zhang, Sabine De Bedout, Jay Mei & Asher Chanan-Khan. (2016) Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*. Leukemia & Lymphoma 57:6, pages 1291-1299.
Read now
Lev Shvidel & Alain Berrebi. (2016) Pitting new treatments for chronic lymphocytic leukemia against old ones: how do they fare?. Expert Review of Hematology 9:3, pages 245-254.
Read now
Michaela Semeraro, Erika Vacchelli, Alexander Eggermont , Jerome Galon, L Zitvogel, G Kroemer & Lorenzo Galluzzi. (2013) Trial Watch: Lenalidomide-based immunochemotherapy. OncoImmunology 2:11.
Read now
Mohammed ZH Farooqui & Adrian Wiestner. (2013) Ibrutinib for the treatment of chronic lymphocytic leukemia. Expert Opinion on Orphan Drugs 1:11, pages 925-933.
Read now

Articles from other publishers (40)

Francesco Paolo Tambaro & William G Wierda. (2020) Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations. The Lancet Haematology 7:2, pages e168-e176.
Crossref
Farrukh T. Awan & John C. Byrd. 2020. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology 1850 1871.e5 .
Amina Taleb B.. (2019) Tumour flare reaction in cancer treatments. Anti-Cancer Drugs 30:9, pages 953-958.
Crossref
Ota Fuchs. (2019) Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs. Cardiovascular & Hematological Disorders-Drug Targets 19:1, pages 51-78.
Crossref
Gareth P. Gregory & Jake Shortt. 2019. Textbook of Palliative Care. Textbook of Palliative Care 1421 1435 .
Georg Aue, Clare Sun, Delong Liu, Jae-Hyun Park, Stefania Pittaluga, Xin Tian, Elinor Lee, Susan Soto, Janet Valdez, Irina Maric, Maryalice Stetler-Stevenson, Constance Yuan, Yusuke Nakamura, Pawel Muranski & Adrian Wiestner. (2018) Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia. The Journal of Immunology 201:7, pages 1967-1974.
Crossref
Alexander Egle, Michael Steurer, Thomas Melchardt, Lukas Weiss, Franz Josef Gassner, Nadja Zaborsky, Roland Geisberger, Kemal Catakovic, Tanja Nicole Hartmann, Lisa Pleyer, Daniela Voskova, Josef Thaler, Alois Lang, Michael Girschikofsky, Andreas Petzer & Richard Greil. (2018) Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. Annals of Hematology 97:10, pages 1825-1839.
Crossref
John C. ByrdAmy S. Ruppert, Nyla A. HeeremaAlese E. HalvorsonEva HokeMitchell R. SmithJohn E. GodwinStephen CoubanTodd A. FehnigerMichael J. ThirmanMartin S. TallmanFrederick R. AppelbaumRichard M. Stone, Sue RobinsonJulie E. Chang, Sumithra J. MandrekarRichard A. Larson. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advances 2:14, pages 1705-1718.
Crossref
Gareth P. Gregory & Jake Shortt. 2018. Textbook of Palliative Care. Textbook of Palliative Care 1 15 .
Bruce D. Cheson, Sari Heitner Enschede, Elisa Cerri, Monali Desai, Jalaja Potluri, Nicole Lamanna & Constantine Tam. (2017) Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents. The Oncologist 22:11, pages 1283-1291.
Crossref
G Galletti, F Caligaris-Cappio & M T S Bertilaccio. (2016) B cells and macrophages pursue a common path toward the development and progression of chronic lymphocytic leukemia. Leukemia 30:12, pages 2293-2301.
Crossref
Christian Maurer, Natali Pflug, Jasmin Bahlo, Sandra Kluth, Christina Rhein, Paula Cramer, Carolin Gross-Ophoff, Petra Langerbeins, Anna-Maria Fink, Barbara Eichhorst, Karl-Anton Kreuzer, Norbert Fischer, Eugen Tausch, Stephan Stilgenbauer, Sebastian Böttcher, Hartmut Döhner, Michael Kneba, Martin Dreyling, Mascha Binder, Michael Hallek, Clemens-Martin Wendtner, Manuela Bergmann & Kirsten Fischer. (2016) Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. European Journal of Haematology 97:3, pages 253-260.
Crossref
Liang Liang, Ming Zhao, Yuan-chao Zhu, Xin Hu, Li-ping Yang & Hui Liu. (2016) Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis. Annals of Hematology 95:9, pages 1473-1482.
Crossref
A Bühler, C-M Wendtner, T J Kipps, L Rassenti, G A M Fraser, A-S Michallet, P Hillmen, J Dürig, S A Gregory, M Kalaycio, T Aurran-Schleinitz, L Trentin, J G Gribben, A Chanan-Khan, B Purse, J Zhang, S De Bedout, J Mei, M Hallek & S Stilgenbauer. (2016) Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer Journal 6:3, pages e404-e404.
Crossref
Scott C. Howard, Steven Trifilio, Tara K. Gregory, Nadine Baxter & Ali McBride. (2016) Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Annals of Hematology 95:4, pages 563-573.
Crossref
Spencer H. Bachow & Nicole Lamanna. (2016) Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting. Current Hematologic Malignancy Reports 11:1, pages 61-70.
Crossref
Bradley Heraly & Vicki A. Morrison. (2015) How I treat chronic lymphocytic leukemia in older patients. Journal of Geriatric Oncology 6:5, pages 333-340.
Crossref
Nitin Jain & Susan O’Brien. (2015) Initial treatment of CLL: integrating biology and functional status. Blood 126:4, pages 463-470.
Crossref
Kami Maddocks, Lai Wei, Darlene Rozewski, Yao Jiang, Yuan Zhao, Mikhil Adusumilli, William E. Pierceall, Camille Doykin, Michael H. Cardone, Jeffrey A. Jones, Joseph Flynn, Leslie A. Andritsos, Michael R. Grever, John C. Byrd, Amy J. Johnson, Mitch A. Phelps & Kristie A Blum. (2015) Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL). American Journal of Hematology 90:4, pages 327-333.
Crossref
Kyle Crassini. (2015) Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date. World Journal of Clinical Cases 3:8, pages 694.
Crossref
E. Tausch & S. Stilgenbauer. (2014) Chronische lymphatische Leuk?mie: aktuelle Standards und neue Therapieans?tzeChronic lymphocytic leukemia: current standards and novel approaches. Der Internist 55:12, pages 1400-1409.
Crossref
Monika Podhorecka, Justyna Markowicz, Agnieszka Szymczyk & Johannes Pawlowski. (2014) Target Therapy in Hematological Malignances: New Monoclonal Antibodies. International Scholarly Research Notices 2014, pages 1-16.
Crossref
Arnon P. KaterSanne H. ToninoAlexander Egle & Alan G. Ramsay. (2014) How does lenalidomide target the chronic lymphocytic leukemia microenvironment?. Blood 124:14, pages 2184-2189.
Crossref
Margaret A. Lindorfer, Joost M. Bakker, Paul W.H.I. Parren & Ronald P. Taylor. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies 1733 1774 .
Kami Maddocks, Amy S. Ruppert, Rebekah Browning, Jeffrey Jones, Joseph Flynn, Cheryl Kefauver, Yue Gao, Yao Jiang, Darlene M. Rozewski, Ming Poi, Mitch A. Phelps, Erica Harper, Amy J. Johnson, John C. Byrd & Leslie A. Andritsos. (2014) A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia. Leukemia Research 38:9, pages 1025-1029.
Crossref
Christine I. Chen, Harminder Paul, Trina Wang, Lisa W. Le, Nimisha Dave, Vishal Kukreti, Ellen Nong Wei, Anthea Lau, Peter Leif Bergsagel & Suzanne Trudel. (2014) Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia. British Journal of Haematology 165:5, pages 731-733.
Crossref
John C. Byrd & Joseph M. Flynn. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology 1958 1978.e7 .
Mei Wu, Akintunde Akinleye & Xiongpeng Zhu. (2013) Novel agents for chronic lymphocytic leukemia. Journal of Hematology & Oncology 6:1.
Crossref
Kirsty Cuthill & Stephen Devereux. (2013) How I treat patients with relapsed chronic lymphocytic leukaemia. British Journal of Haematology 163:4, pages 423-435.
Crossref
Nadia Khan & Bruce D. Cheson. (2013) PTCL Therapies. American Journal of Therapeutics 20:5, pages 524-533.
Crossref
Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C. Badoux, Steliana Calin, James M. Reuben, Susan O’Brien, Steven M. Kornblau, Hagop M. Kantarjian, Hui Gao & Alessandra Ferrajoli. (2013) Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood 122:5, pages 734-737.
Crossref
Florence Cymbalist. (2013) LLC: physiopathologie, diagnostic et approche th?rapeutique. Revue Francophone des Laboratoires 2013:452, pages 61-71.
Crossref
Alan G. Ramsay, Rachel Evans, Shahryar Kiaii, Lena Svensson, Nancy Hogg & John G. Gribben. (2013) Chronic lymphocytic leukemia cells induce defective LFA-1–directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood 121:14, pages 2704-2714.
Crossref
Andrea Schnaiter & Stephan Stilgenbauer. (2013) 17p Deletion in Chronic Lymphocytic Leukemia. Hematology/Oncology Clinics of North America 27:2, pages 289-301.
Crossref
Angela SchulzClaudia DürrThorsten Zenz, Hartmut Döhner, Stephan Stilgenbauer, Peter LichterMartina Seiffert. (2013) Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment. Blood 121:13, pages 2503-2511.
Crossref
Deepesh P. Lad, Pankaj Malhotra & Subhash Varma. (2012) Chronic Lymphocytic Leukemia: Inception to Cure: Are We There?. Indian Journal of Hematology and Blood Transfusion 29:1, pages 1-10.
Crossref
Christine I. Chen. (2012) Lenalidomide Alone and in Combination for Chronic Lymphocytic Leukemia. Current Hematologic Malignancy Reports 8:1, pages 7-13.
Crossref
S. Stilgenbauer & M. Hallek. (2013) Chronische lymphatische Leuk?mieChronic lymphocytic leukemia. Der Internist 54:2, pages 164-170.
Crossref
Ana Pilar Gonz?lez-Rodr?guez, Angel R. Payer, Andrea Acebes-Huerta, Leticia Huergo-Zapico, Monica Villa-Alvarez, Esther Gonzalez-Garc?a & Segundo Gonzalez. (2013) Lenalidomide and Chronic Lymphocytic Leukemia. BioMed Research International 2013, pages 1-9.
Crossref
Donna Reece, C. Tom Kouroukis, Richard LeBlanc, Michael Sebag, Kevin Song & John Ashkenas. (2012) Practical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus. Advances in Hematology 2012, pages 1-14.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.